카미시날
Camicinal| 임상 데이터 | |
|---|---|
| 기타 이름 | GSK962040 |
| 식별자 | |
| |
| CAS 번호 | |
| PubChem CID | |
| 켐스파이더 | |
| 유니 | |
| 케그 | |
| ECHA 정보 카드 | 100.158.139 |
| 화학 및 물리 데이터 | |
| 공식 | C25H33FN4O |
| 몰 질량 | 424.564 g/120−1 |
| 3D 모델(JSmol) | |
| |
| |
카미시날은 위마비증 [1][2][3]치료를 위한 운동작용제이다.
레퍼런스
- ^ Barshop K, Kuo B (January 2015). "The investigational drug camicinal for the treatment of gastroparesis". Expert Opinion on Investigational Drugs. 24 (1): 133–140. doi:10.1517/13543784.2015.975792. PMID 25341626. S2CID 25896703.
- ^ Hobson R, Farmer AD, Dewit OE, O'Donnell M, Hacquoil K, Robertson D, et al. (November 2015). "The effects of camicinal, a novel motilin agonist, on gastro-esophageal function in healthy humans-a randomized placebo controlled trial". Neurogastroenterology and Motility. 27 (11): 1629–37. doi:10.1111/nmo.12663. PMID 26348542.
- ^ Chapman MJ, Deane AM, O'Connor SL, Nguyen NQ, Fraser RJ, Richards DB, et al. (August 2016). "The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial". Critical Care. 20 (1): 232. doi:10.1186/s13054-016-1420-4. PMC 4967996. PMID 27476581.